Trachiotis G D, Johnston T S, Vega J D, Crocker I R, Chesnut N, Lutz J F, Smith A L, Kanter K R
Division of Cardiothoracic Surgery, Emory University, Atlanta, Georgia, USA.
J Heart Lung Transplant. 1998 Nov;17(11):1045-8.
Nine heart transplant recipients were treated with single-field total lymphoid irradiation (TLI) for early (<1 year) or late (>1 year) rejection that was refractory to multiple regimens of immunosuppressive therapy. For patients with early rejection (n = 6), the rejection frequency (rejections/patient/month) decreased from pre-TLI of 1.63 to post-TLI of .02 (p < .001), and for patients with late rejection (n = 3), the rejection frequency decreased from pre-TLI of .23 to post-TLI of .05 (p < .02). The reduced rejection frequencies have been maintained for a mean follow-up of 28.6 (8 to 78) months, and adverse events during or late after TLI were uncommon. Single-field TLI is a safe and effective technique in the management of refractory rejection early or late after heart transplantation.
九名心脏移植受者接受了单野全淋巴照射（TLI）治疗，用于治疗对多种免疫抑制治疗方案均难治的早期（<1年）或晚期（>1年）排斥反应。对于早期排斥反应患者（n = 6），排斥反应频率（排斥反应数/患者/月）从TLI治疗前的1.63降至TLI治疗后的0.02（p < 0.001），对于晚期排斥反应患者（n = 3），排斥反应频率从TLI治疗前的0.23降至TLI治疗后的0.05（p < 0.02）。排斥反应频率降低的情况在平均28.6（8至78）个月的随访中一直保持，TLI期间或之后的不良事件并不常见。单野TLI是心脏移植后早期或晚期难治性排斥反应管理中的一种安全有效的技术。
